Kangpu's Novel Molecular Glue Modulator KPG-818 Receives IND Approval in China for Multiple Myeloma Treatment
核心洞察
Kangpu Biopharmaceuticals (搜索) has secured IND approval from China's NMPA for KPG-818, a novel oral molecular glue modulator targeting relapsed/refractory multiple myeloma (搜索).
KPG-818 demonstrates potent degradation of Aiolos (搜索) and Ikaros (搜索) transcription factors, showing immunomodulatory, anti-angiogenic, and anti-tumor properties.
Phase I trials in the US have shown promising safety and efficacy in heavily pretreated RRMM patients who previously received immunomodulatory drugs, proteasome inhibitors, and CD38 antibodies.
Kangpu Biopharmaceuticals (搜索) announced today that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for KPG-818, advancing the treatment landscape for relapsed/refractory multiple myeloma (搜索) (RRMM).
Mechanism of Action and Drug Properties
KPG-818 represents a novel approach in multiple myeloma (搜索) treatment as an oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN (搜索). The drug exhibits high binding affinity to cereblon (CRBN) and effectively triggers the degradation of Aiolos (搜索) (IKZF3) and Ikaros (搜索) (IKZF1), key zinc-finger transcription factors involved in B-cell development. This mechanism enables KPG-818 to deliver multiple therapeutic effects, including immunomodulation, anti-angiogenesis, and direct anti-tumor activity.
Promising Clinical Results
The completed Phase I clinical trial in the United States has yielded encouraging results for KPG-818 in treating various hematological tumors. The drug demonstrated favorable safety and tolerability profiles, along with promising pharmacokinetic characteristics. Notably, KPG-818 showed therapeutic potential in heavily pretreated RRMM patients who had previously undergone multiple lines of therapy, including:
- Two immunomodulatory drugs (lenalidomide and pomalidomide)
- At least one proteasome inhibitor (bortezomib, ixazomib, or carfilzomib)
- A CD38 monoclonal antibody (daratumumab or isatuximab)
Development Pipeline and Company Focus
Kangpu Biopharmaceuticals (搜索), a clinical-stage biotechnology company, continues to advance its robust pipeline of potential first-in-class and best-in-class drug candidates. The company leverages proprietary technology platforms, including NeoMIDES®, gDACs®, and X-SYNERGY®, to develop innovative therapeutics targeting solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders.
The IND approval in China marks a significant milestone in KPG-818's development program and represents an important step forward in addressing the unmet needs of multiple myeloma (搜索) patients who have exhausted current treatment options.